Abstracts tagged "Allopurinol"

Abstract Number: 163 • 2014 ACR/ARHP Annual Meeting
Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat
Thomas Bardin¹, Gérard Chales², Tristan Pascart³, René-Marc Flipo⁴, Jean-Claude Roujeau⁵, Aurélie Delayen⁶ and Pierre Clerson⁷, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ³Rheumatology, Saint-Philibert Hospital, LOMME, France, ⁴rheumatology, Rene Salengro hospital, Lille, France, ⁵Dermatology, University Paris Est, Créteil, France, ⁶Orgamétrie biostatistiques, Roubaix, France, ⁷Orgametrie, Roubaix, France
Background/Purpose: Allopurinol can lead to skin toxicity. Minor skin reactions are reported in 2-4% of patients and life threatening severe cutaneous reactions (SCARs) in 0.1-0.4%.…
Abstract Number: 46 • 2014 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout
Seoyoung C. Kim¹, John D. Seeger², Jun Liu³ and Daniel H. Solomon⁴, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of type 2 diabetes (T2D). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the main…
Abstract Number: L10 • 2014 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Two Phase III Clinical Trials: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR 1 and 2)
Kenneth G. Saag¹, Scott Adler², Nihar Bhakta³, Maple Fung³, Jeff Kopicko³, Chris Storgard³ and Thomas Bardin⁴, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²AstraZeneca Pharmaceuticals, Wilmington, DE, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France
Background/Purpose: Inadequate response to allopurinol monotherapy is common. Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) under investigation for treatment of gout in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].